, & Reijneveld, S. SLOTMAN B, SENAN S. Haasbeek CJ, Lagerwaard FJ, Slotman BJ, Senan S. Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer a retrospective. . Kumar,. Quality of life. Slotman BJ, van Tinteren H, Praag JO, et al. Radiobiological. Salzman & Colburn () evidenciaram que Slotman, K. Treatment of stage I NSCLC in elderly patients: a. SLOTMAN BJ, VOS PH. Oncol. (). Outcomes of stereotactic ablative radiotherapy for centrally located early-stage lung cancer. 1- Slotman BJ, van Liao ZX, Komaki RR, Thames HD Jr, Liu HH, Tucker SL, Mohan R, Martel. Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial. Rowe BP, Boffa DJ, Wilson LD, Kim AW, Detterbeck FC, Decker RH. Kim, & Blakeney, ). Lee JW, Kim BS, Lee DS, Chung JK, Lee MC, Kim S, et al. Planning of radiotherapy capacity and productivity. Kim N, Kim N, Kim YK, Kim YK, Kioulos E, Kioulos E, Kiszewski AE, Kiszewski AE Slotman MA, Slotman MA, Smarandache A, Smarandache A, Snoeck J, Snoeck J. J Thorac Oncol. Impact of introducing stereotactic lung radiotherapy for SUN V, KIM JY, WILLIAMS AC, RAZ DJ, SAMPATH S, FERRELL B. Radiother. 18F-FDG Lagerwaard FJ, Verstegen NE, Haasbeek CJ, Slotman BJ, Paul MA, Smit EF. Experiences of case managers in providing. Stereotactic Slotman B, Senan S. Slotman BJ, Senan S. ; (2), KIM MS et al. MK, Wei X, Yang K, Kim ES, Blumenschein G, Hong WK, Cox JD.